cp wire

CP Wire Articles

Horizon Pharma plc (Nasdaq:HZNP) announced on 5/8/18 that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643... read more

Tue, 05/8/18 - 09:58 am
CP Staff

The U.S. Food and Drug Administration announced on 5/7/18 that it has permitted marketing of Hemospray, by Wilson-Cook Medical Inc., a new device used to help control certain types of bleeding in... read more

Mon, 05/7/18 - 07:35 pm
CP Staff

AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international... read more

Mon, 05/7/18 - 05:22 pm
CP Staff

Novavax, Inc. (Nasdaq:NVAX) announced on 5/7/18 it has reached a significant milestone in the Prepare Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle... read more

Mon, 05/7/18 - 02:39 pm
CP Staff

Geisinger President and CEO David T. Feinberg, M.D., MBA, announced on 5/6/18 that the Pennsylvania-based health system is expanding its successful genomics program beyond the realm of research... read more

Mon, 05/7/18 - 11:07 am
CP Staff

Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in patients with major... read more

Mon, 05/7/18 - 09:10 am
CP Staff

Evolve Biologics, a division of Therapure Biopharma Inc.,  announced  on 5/4/18 that it has dosed the first pediatric patient in its Phase III multicenter clinical trial of PlasmaCap IG (... read more

Fri, 05/4/18 - 01:17 pm
CP Staff

Boehringer Ingelheim announced on 5/4/18 that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states.... read more

Fri, 05/4/18 - 10:22 am
CP Staff

The FDA extended the PDUFA goal date of Akcea's hereditary TTR amyloidosis drug inotersen to October 6, 2018.

“The FDA has extended the review period for TEGSEDI and has assigned a new... read more

Fri, 05/4/18 - 09:54 am
CP Staff

Integer Holdings Corporation (“Integer”) (NYSE:ITGR), a leading medical device outsource manufacturer, today announced that it has entered into an agreement to sell its Advanced Surgical and... read more

Thu, 05/3/18 - 06:24 pm
CP Staff

A new research study by scientists in Australia and the US provides a possible explanation for why clinical trials of drugs reducing proteins in the brain that were thought to cause dementia and... read more

Thu, 05/3/18 - 06:11 pm
CP Staff
  • Coherus received a complete response letter from th FDA in June 2017
  • Competitors Mylan and Biocon received a CRL in October of 2017
  • Neulasta has generated $20 billion in... read more
Thu, 05/3/18 - 02:45 pm
CP Staff

CytRx Corporation (NASDAQ: CYTR), announced on 5/3/18 that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive management team, as President and... read more

Thu, 05/3/18 - 12:25 pm
CP Staff

Hemostemix Inc. (TSX VENTURE:HEM) announced on 5/3/18 that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first patient was... read more

Thu, 05/3/18 - 12:11 pm
CP Staff

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced on 5/3/18 that the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on a pivotal study design for... read more

Thu, 05/3/18 - 11:12 am
CP Staff

Bristol-Myers Squibb Company (NYSE: BMY) announced on 5/3/18 that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy(... read more

Thu, 05/3/18 - 09:24 am
CP Staff
  • Companies will partner to advance multispecific antibodies in up to seven discrete projects, including one program against an undisclosed target currently in lead selection
  • Invenra... read more
Wed, 05/2/18 - 08:46 pm
CP Staff

Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming... read more

Wed, 05/2/18 - 08:12 pm
CP Staff
  • Phase I trials indicated BN-Brachyury is well tolerated
  • Initiating phase 2 study in patients with metastatic chordoma
  • Also has the potential to treat: triple negative breast... read more
Wed, 05/2/18 - 01:20 pm
CP Staff


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.